Protective and toxic roles of dopamine in Parkinson's disease

Journal of Neurochemistry

Volumn 129, Issue 6, 2014, Pages 898-915

  Segura Aguilar, Juan ^a   Paris, Irmgard ^a,b   Muñoz, Patricia ^a   Ferrari, Emanuele ^c   Zecca, Luigi ^c   Zucca, Fabio A ^c  

^a UNIVERSITY OF CHILE   (Chile)

^b UNIVERSIDAD SANTO TOMÁS   (Chile)

^c INSTITUTE OF BIOMEDICAL TECHNOLOGIES   (Italy)

Author keywords

5 6 indolequinone; aminochrome; dopa mine o quinone; dopamine; neurodegeneration; neuromelanin; Parkinson s disease

Indexed keywords

5,6 INDOLEQUINONE; ADENOSINE TRIPHOSPHATASE; ADENOSINE TRIPHOSPHATASE 13A1; ALPHA SYNUCLEIN; AMINE OXIDASE (FLAVIN CONTAINING); AMINOCHROME; CATECHOL ORTHO METHYLTRANSFERASE; DIHYDROLIPOAMIDE DEHYDROGENASE; DJ 1 PROTEIN; DOPAMINE; DOPAMINE O QUINONE; LEUCINE RICH REPEAT KINASE 2; METHYLTRANSFERASE; NEUROMELANIN; PROTEASOME; PROTEIN PINK 1; PROTEIN SERINE THREONINE KINASE; QUINONE DERIVATIVE; UBIQUITIN PROTEIN LIGASE E3; UBIQUITIN THIOLESTERASE; UBIQUITIN THIOLESTERASE L1; UNCLASSIFIED DRUG;

DEAMINATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DOPAMINE METABOLISM; DOPAMINERGIC NERVE CELL; GENETIC ANALYSIS; HUMAN; LYSOSOME; MOTOR DYSFUNCTION; NERVE CELL NECROSIS; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NEUROPATHOLOGY; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OXIDATION; OXIDATIVE STRESS; PARKINSON DISEASE; POLYMERIZATION; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN DEGRADATION; REVIEW; SIGNAL TRANSDUCTION; SUBSTANTIA NIGRA;

5,6-INDOLEQUINONE; AMINOCHROME; DOPA-MINE O-QUINONE; DOPAMINE; NEURODEGENERATION; NEUROMELANIN; PARKINSON′S DISEASE;

ANIMALS; DOPAMINE; GLUTATHIONE; HUMANS; INDOLEQUINONES; MELANINS; MONOAMINE OXIDASE; PARKINSON DISEASE; QUINONES;

EID: 84902326763     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/jnc.12686     Document Type: Review

References (176)

1. Abbas N., Lücking C. B., Ricard S., et al,. (1999) A wide variety of mutations in the parkin gene are responsible for autosomal recessive parkinsonism in Europe. French Parkinson's Disease Genetics Study Group and the European Consortium on Genetic Susceptibility in Parkinson's Disease. Hum. Mol. Genet. 8, 567-574.
2. Arriagada A., Paris I., Sanchez de las Matas M. J., et al,. (2004) On the neurotoxicity of leukoaminochrome o-semiquinone radical derived of dopamine oxidation: mitochondria damage, necrosis and hydroxyl radical formation. Neurobiol. Dis. 16, 468-477.
3. Bach A. W. J., Lan N. C., Johnson D. L., Abell C. W., Bemkenek M. E., Kwan S. W., Seeburg P. H., and, Shih J. C., (1988) cDNA cloning of human liver monoamine oxidase A and B: molecular basis of differences in enzymatic properties. Proc. Natl Acad. Sci. USA 85, 4934-4938.
4. Baez S., Linderson Y., and, Segura-Aguilar J., (1995) Superoxide dismutase and catalase enhance autoxidation during one-electron reduction of aminochrome by NADPH-cytochrome P-450 reductase. Biochem. Mol. Med. 54, 12-18.
5. Baez S., Segura-Aguilar J., Widersten M., Johansson A. S., and, Mannervik B., (1997) Glutathione transferases catalyse the detoxication of oxidized metabolites (o-quinones) of catecholamines and may serve as an antioxidant system preventing degenerative cellular processes. Biochem. J. 324, 25-28.
6. Banati R. B., Daniel S. E., and, Blunt S. B., (1998) Glial pathology but absence of apoptotic nigral neurons in long-standing Parkinson's disease. Mov. Disord. 13, 221-227.
7. Bendor J. T., Logan T. P., and, Edwards R. H., (2013) The function of α-synuclein. Neuron 79, 1044-1066.
8. Bisaglia M., Mammi S., and, Bubacco L., (2007) Kinetic and structural analysis of the early oxidation products of dopamine: analysis of the interactions with alpha-synuclein. J. Biol. Chem. 282, 15597-15605.
9. Bisaglia M., Soriano M. E., Arduini I., Mammi S., and, Bubacco L., (2010) Molecular characterization of dopamine-derived quinones reactivity toward NADH and glutathione: implications for mitochondrial dysfunction in Parkinson disease. Biochim. Biophys. Acta. 1802, 699-706.
10. Blackinton J., Lakshminarasimhan M., Thomas K. J., Ahmad R., Greggio E., Raza A. S., Cookson M. R., and, Wilson M. A., (2009) Formation of a stabilized cysteine sulfinic acid is critical for the mitochondrial function of the parkinsonism protein DJ-1. J. Biol. Chem. 284, 6476-6485.
11. Block M. L., Zecca L., and, Hong J., (2007) Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat. Rev. Neurosci. 8, 57-69.
12. Bohic S., Murphy K., Paulus W., Cloetens P., Salomé M., Susini J., and, Double K., (2008) Intracellular chemical imaging of the developmental phases of human neuromelanin using synchrotron X-ray microspectroscopy. Anal. Chem. 80, 9557-9566.
13. Bonifati V., Rizzu P., van Baren M. J., et al,. (2003) Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 299, 256-259.
14. Braak H., Ghebremedhin E., Rüb U., Bratzke H., and, Del Tredici K., (2004) Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res. 318, 121-134.
15. Bush W. D., Garguilo J., Zucca F. A., Albertini A., Zecca L., Edwards G. S., Nemanich R. J., and, Simon J. D., (2006) The surface oxidation potential of human neuromelanin reveals a spherical architecture with a pheomelanin core and a eumelanin surface. Proc. Natl Acad. Sci. USA 103, 14785-14789.
16. Canet-Avilés R. M., Wilson M. A., Miller D. W., Ahmad R., McLendon C., Bandyopadhyay S., Baptista M. J., Ringe D., Petsko G. A., and, Cookson M. R., (2004) The Parkinson's disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization. Proc. Natl Acad. Sci. USA 101, 9103-9108.
17. Carstam R., Brinck C., Hindemith-Augustsson A., Rorsman H., and, Rosengren E., (1991) The neuromelanin of the human substantia nigra. Biochim. Biophys. Acta 1097, 152-160.
18. Cartier E. A., Parra L. A., Baust T. B., Quiroz M., Salazar G., Faundez V., Egaña L., and, Torres G. E., (2010) A biochemical and functional protein complex involving dopamine synthesis and transport into synaptic vesicles. J. Biol. Chem. 151, 957-966.
19. Cases O., Seif I., Grimsby J., et al,. (1995) Aggressive behavior and altered amounts of brain serotonin and norepinephrine in mice lacking MAOA. Science 268, 1763-1766.
20. Chen J., Song J., Yuan P., Tian Q., Ji Y., Ren-Patterson R., Liu G., Sei Y., and, Weinberger D. R., (2011) Orientation and cellular distribution of membrane-bound catechol-O-methyltransferase in cortical neurons: implications for drug development. J. Biol. Chem. 286, 34752-34760.
21. Cheng F. C., Kuo J. S., Chia L. G., and, Dryhurst G., (1996) Elevated 5-S-cysteinyldopamine/homovanillic acid ratio and reduced homovanillic acid in cerebrospinal fluid: possible markers for and potential insights into the pathoetiology of Parkinson's disease. J. Neural Transm. 103, 433-446.
22. Conway K. A., Rochet J. C., Bieganski R. M., and, Lansbury P. T., Jr, (2001) Kinetic stabilization of the a-synuclein protofibril by a dopamine- α-synuclein adduct. Science 294, 1346-1349.
23. Coon S., Stark A., Peterson E., Gloi A., Kortsha G., Pounds J., Chettle D., and, Gorell J., (2006) Whole-body lifetime occupational lead exposure and risk of Parkinson's disease. Environ. Health Perspect. 114, 1872-1876.
24. Cuervo A. M., Stefanis L., Fredenburg R., Lansbury P. T., and, Sulzer D., (2004) Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science 305, 1292-1295.
25. Dagnino-Subiabre A., Cassels B. K., Baez S., Johansson A. S., Mannervik B., and, Segura-Aguilar J., (2000) Glutathione transferase M2-2 catalyzes conjugation of dopamine and dopa o-quinones. Biochem. Biophys. Res. Commun. 274, 32-36.
26. D'Amato R. J., Lipman Z. P., and, Snyder S. H., (1986) Selectivity of the parkinsonian neurotoxin MPTP: toxic metabolite MPP+ binds to neuromelanin. Science 231, 987-989.
27. Dexter D. T., Wells F. R., Agid F., Agid Y., Lees A. J., Jenner P., and, Marsden C. D., (1987) Increased nigral iron content in postmortem parkinsonian brain. Lancet 2, 1219-1220.
28. Dexter D. T., Wells F. R., Lees A. J., Agid F., Agid Y., Jenner P., and, Marsden C. D., (1989) Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J. Neurochem. 52, 1830-1836.
29. Díaz-Véliz G., Mora S., Dossi M. T., Gõmez P., Arriagada C., Montiel J., Aboitiz F., and, Segura-Aguilar J., (2002) Behavioral effects of aminochrome and dopachrome injected in the rat substantia nigra. Pharmacol. Biochem. Behav. 73, 843-850.
30. Díaz-Véliz G., Mora S., Gõmez P., Dossi M. T., Montiel J., Arriagada C., Aboitiz F., and, Segura-Aguilar J., (2004a) Behavioral effects of manganese injected in the rat substantia nigra are potentiated by dicumarol, a DT-diapase inhibitor. Pharmacol. Biochem. Behav. 77, 245-251.
31. Díaz-Véliz G., Mora S., Lungenstrass H., and, Segura-Aguilar J., (2004b) Inhibition of DT-diaphorase potentiates the in vivo neurotoxic effect of intranigral injection of salsolinol in rats. Neurotox. Res. 5, 629-633.
32. Díaz-Véliz G., Paris I., Mora S., Raisman-Vozari R., and, Segura-Aguilar J., (2008) Copper neurotoxicity in rat substantia nigra and striatum is dependent on DT-diaphorase inhibition. Chem. Res. Toxicol. 21, 1180-1185.
33. Dibenedetto D., Rossetti G., Caliandro R., and, Carloni P., (2013) A molecular dynamics simulation-based interpretation of nuclear magnetic resonance multidimensional heteronuclear spectra of α-synuclein dopamine adducts. Biochemistry 52, 6672-6683.
34. Double K. L., Ben-Shachar D., Youdim M. B., Zecca L., Riederer P., and, Gerlach M., (2002) Influence of neuromelanin on oxidative pathways within the human substantia nigra. Neurotoxicol. Teratol. 24, 621-628.
35. Double K. L., Gerlach M., Schünemann V., Trautwein A. X., Zecca L., Gallorini M., Youdim M. B., Riederer P., and, Ben-Shachar D., (2003) Iron-binding characteristics of neuromelanin of the human substantia nigra. Biochem. Pharmacol. 66, 489-494.
36. Earle K. M., (1968) Studies on Parkinson's disease including x-ray fluorescent spectroscopy of formalin fixed brain tissue. J. Neuropathol. Exp. Neurol. 27, 1-14.
37. Ebrahimi-Fakhari D., Wahlster L., and, McLean P. J., (2012) Protein degradation pathways in Parkinson's disease: curse or blessing. Acta Neuropathol. 124, 153-172.
38. Engelen M., Vanna R., Bellei C., Zucca F. A., Wakamatsu K., Monzani E., Ito S., Casella L., and, Zecca L., (2012) Neuromelanins of human brain have soluble and insoluble components with dolichols attached to the melanic structure. PLoS ONE 7, e48490.
39. Eriksen J., Jørgensen T. N., and, Gether U., (2010) Regulation of dopamine transporter function by protein-protein interactions: new discoveries and methodological challenges. J. Neurochem. 113, 27-41.
40. Exner N., Lutz A. K., Haass C., and, Winklhofer K. F., (2012) Mitochondrial dysfunction in Parkinson's disease: molecular mechanisms and pathophysiological consequences. EMBO J. 31, 3038-3062.
41. Fasano M., Bergamasco B., and, Lopiano L., (2006) Modifications of the iron-neuromelanin system in Parkinson's disease. J. Neurochem. 96, 909-916.
42. Faucheux B. A., Martin M. E., Beaumont C., Hauw J. J., Agid Y., and, Hirsch E. C., (2003) Neuromelanin associated redox-Active iron is increased in the substantia nigra of patients with Parkinson's disease. J. Neurochem. 86, 1142-1148.
43. Fedorow H., Pickford R., Hook J. M., Double K. L., Halliday G. M., Gerlach M., Riederer P., and, Garner B., (2005) Dolichol is the major lipid component of human substantia nigra neuromelanin. J. Neurochem. 92, 990-995.
44. Ferrari E., Engelen M., Monzani E., Sturini M., Girotto S., Bubacco L., Zecca L., and, Casella L., (2013) Synthesis and structural characterization of soluble neuromelanin analogs provides important clues to its biosynthesis. J. Biol. Inorg. Chem. 18, 81-93.
45. Foley J. M., and, Baxter D., (1958) On the nature of pigment granules in the cells of the locus coeruleus and substantia nigra. J. Neuropathol. Exp. Neurol. 17, 586-598.
46. Foppoli C., Coccia R., Cini C., and, Rosei M. A., (1997) Catecholamines oxidation by xanthine oxidase. Biochim. Biophys. Acta 1334, 200-206.
47. Fornstedt B., Rosengren E., and, Carlsson A., (1986) Occurrence and distribution of 5-S-cysteinyl derivatives of dopamine, dopa and dopac in the brains of eight mammalian species. Neuropharmacology 25, 451-454.
48. Fuentes P., Paris I., Nassif M., Caviedes P., and, Segura-Aguilar J., (2007) Inhibition of VMAT-2 and DT-diaphorase induce cell death in a substantia nigra-derived cell line-An experimental cell model for dopamine toxicity studies. Chem. Res. Toxicol. 20, 776-783.
49. Galzigna L., De Iuliis A., and, Zanatta L., (2000) Enzymatic dopamine peroxidation in substantia nigra of human brain. Clin. Chim. Acta 300, 131-138.
50. Gautam A. H., and, Zeevalk G. D., (2011) Characterization of reduced and oxidized dopamine and 3,4-dihydrophenylacetic acid, on brain mitochondrial electron transport chain activities. Biochim. Biophys. Acta 1807, 819-828.
51. Geha R. M., Chen K., Wouters J., Ooms F., and, Shih J. C., (2002) Analysis of conserved active site residues in monoamine oxidase A and B and their three-dimensional molecular modeling. J. Biol. Chem. 277, 17209-17216.
52. Gibb W. R., and, Lees A. J., (1991) Anatomy, pigmentation, ventral and dorsal subpopulations of the substantia nigra, and differential cell death in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 54, 388-396.
53. Guillot T. S., and, Miller G. W., (2009) Protective actions of the vesicular monoamine transporter 2 (VMAT2) in monoaminergic neurons. Mol. Neurobiol. 39, 149-170.
54. Giros B., Jaber M., Jones S. R., Wightman R. M., and, Caron M. G., (1996) Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 379, 606-612.
55. Goldstein D. S., Sullivan P., Holmes C., Miller G. W., Alter S., Strong R., Mash D. C., Kopin I. J., and, Sharabi Y., (2013) Determinants of buildup of the toxic dopamine metabolite DOPAL in Parkinson's disease. J. Neurochem. 126, 591-603.
56. Good P. F., Olanow C. W., and, Perl D. P., (1992) Neuromelanin-containing neurons of the substantia nigra accumulate iron and aluminum in Parkinson's disease: a LAMMA study. Brain Res. 593, 343-346.
57. Gorell J. M., Johnson C. C., Rybicki B. A., Peterson E. L., Kortsha G. X., Brown G. G., and, Richardson R. J., (1999) Occupational exposure to manganese, copper, lead, iron, mercury and zinc and the risk of Parkinson's disease. Neurotoxicology 20, 239-247.
58. Graham D. G., Tiffany S. M., Bell W. R. Jr, and, Gutknecht W. F., (1978) Autoxidation versus covalent binding of Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro. Mol. Pharmacol. 14, 644-653.
59. Greggio E., Bergantino E., Carter D., et al,. (2005) Tyrosinase exacerbates dopamine toxicity but is not genetically associated with Parkinson's disease. J. Neurochem. 93, 246-256.
60. Haavik J., (1997) L-DOPA is a substrate for tyrosine hydroxylase. J. Neurochem. 69, 1720-1728.
61. Hastings T. G., (1995) Enzymatic oxidation of dopamine: the role of prostaglandin H synthase. J. Neurochem. 64, 919-924.
62. Harrison W. H., Whisler W. W., and, Hill B. J., (1968) Catecholamine oxidation and ionization properties indicated from the H+ release, tritium exchange, and spectral changes which occur during ferricyanide oxidation. Biochemistry 7, 3089-3094.
63. Hattori N., Matsumine H., Asakawa S., et al,. (1998) Point mutations (Thr240Arg and Gln311Stop) [correction of Thr240Arg and Ala311Stop] in the Parkin gene. Biochem. Biophys. Res. Commun. 249, 754-758.
64. Hauser D. N., and, Hastings T. G., (2013) Mitochondrial dysfunction and oxidative stress in Parkinson's disease and monogenic parkinsonism. Neurobiol. Dis. 51, 35-42.
65. Hauser D. N., Dukes A. A., Mortimer A. D., and, Hastings T. G., (2013) Dopamine quinone modifies and decreases the abundance of the mitochondrial selenoprotein glutathione peroxidase 4. Free Radic Biol Med. 65, 419-427.
66. Hawkes C. H., Del Tredici K., and, Braak H., (2010) A timeline for Parkinson's disease. Parkinsonism Relat. Disord. 16, 79-84.
67. Hawley M. D., Tatawawadi S. V., Piekarski S., and, Adams R. N., (1967) Electrochemical studies of the oxidation pathways of catecholamines. J. Am. Chem. Soc. 89, 447-450.
68. Healy D. G., Abou-Sleiman P. M., and, Wood N. W., (2004) Genetic causes of Parkinson's disease: UCHL-1. Cell Tissue Res. 318, 189-194.
69. Hirsch E., Graybiel A. M., and, Agid Y. A., (1988) Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature 334, 345-348.
70. Huenchuguala S., Muñoz P., Zavala P., et al,. (2014) Glutathione transferase M2 protects glioblastoma cells against aminochrome toxicity by preventing autophagy and lysosome dysfunction. Autophagy 10, 52-64.
71. Ikemoto K., Nagatsu I., Ito S., King R. A., Nishimura A., and, Nagatsu T., (1998) Does tyrosinase exist in neuromelanin-pigmented neurons in the human substantia nigra? Neurosci. Lett. 253, 198-200.
72. Irrcher I., Aleyasin H., Seifert E. L., et al,. (2010) Loss of the Parkinson's disease-linked gene DJ-1 perturbs mitochondrial dynamics. Hum. Mol. Genet. 19, 3734-3746.
73. d'Ischia A., Napolitano A., and, Prota G., (1987) Sulphydryl compounds in melanogenesis. Part I. Reaction of cysteine and glutathione with 5,6-dihydroxyindoles. Tetrahedron 43, 5351-5356.
74. Ito S., (2006) Encapsulation of a reactive core in neuromelanin. Proc. Natl Acad. Sci. USA 103, 14647-14648.
75. Ito S., and, Wakamatsu K., (2008) Chemistry of mixed melanogenesis- pivotal roles of dopaquinone. Photochem. Photobiol. 84, 582-592.
76. Jellinger K., Kienzl E., Rumpelmair G., Riederer P., Stachelberger H., Ben-Shachar D., and, Youdim M. B., (1992) Iron-melanin complex in substantia nigra of parkinsonian brains: an x-ray microanalysis. J. Neurochem. 59, 1168-1171.
77. Jimenez M., Garcia-Carmona F., Garcia-Canovas F., Iborra J. L., Lozano J. A., and, Martinez F., (1984) Chemical intermediates in dopamine oxidation by tyrosinase, and kinetic studies of the process. Arch. Biochem. Biophys. 235, 438-448.
78. Jones S. R., Gainetdinov R. R., Jaber M., Giros B., Wightman R. M., and, Caron M. G., (1998) Profound neuronal plasticity in response to inactivation of the dopamine transporter. Proc. Natl. Acad. Sci. U S A 95, 4029-4034.
79. Kachergus J., Mata I. F., Hulihan M., et al,. (2005) Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations. Am. J. Hum. Genet. 76, 672-680.
80. Kalia L. V., Kalia S. K., McLean P. J., Lozano A. M., and, Lang A. E., (2013) α-Synuclein oligomers and clinical implications for Parkinson disease. Ann. Neurol. 73, 155-169.
81. Karlsson O., and, Lindquist N. G., (2013) Melanin affinity and its possible role in neurodegeneration. J. Neural. Transm. 120, 1623-1630.
82. Kastner A., Hirsch E. C., Lejeune O., Javoy-Agid F., Rascol O., and, Agid Y., (1992) Is the vulnerability of neurons in the substantia nigra of patients with Parkinson's disease related to their neuromelanin content? J. Neurochem. 59, 1080-1109.
83. Kitada T., Asakawa S., Hattori N., Matsumine H., Yamamura Y., Minoshima S., Yokochi M., Mizuno Y., and, Shimizu N., (1998) Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392, 605-608.
84. Kuhn D. M., and, Arthur R., Jr, (1998) Dopamine inactivates tryptophan hydroxylase and forms a redox-cycling quinoprotein: possible endogenous toxin to serotonin neurons. J. Neurosci. 18, 7111-7117.
85. Langston J. W., Forno L. S., Tetrud J., Reeves A. G., Kaplan J. A., and, Karluk D., (1999) Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann. Neurol. 46, 598-605.
86. Larsson B. S., (1993) Interaction between chemicals and melanin. Pigment Cell Res. 6, 127-133.
87. LaVoie M. J., Ostaszewski B. L., Weihofen A., Schlossmacher M. G., and, Selkoe D. J., (2005) Dopamine covalently modifies and functionally inactivates parkin. Nat. Med. 11, 1159-1161.
88. Li H., and, Dryhurst G., (1997) Irreversible inhibition of mitochondrial complex I by 7-(2-Aminoethyl)-3,4-dihydro-5-hydroxy-2H-1,4-benzothiazine-3- carboxyli c acid (DHBT-1): a putative nigral endotoxin of relevance to Parkinson's disease. J. Neurochem. 69, 1530-1541.
89. Ligon L. A., and, Steward O., (2000) Role of microtubules and actin filaments in the movement of mitochondria in the axons and dendrites of cultured hippocampal neurons. J. Comp. Neurol. 427, 351-361.
90. Lindquist N. G., Larsson B. S., and, Lydén-Sokolowski A., (1987) Neuromelanin and its possible protective and destructive properties. Pigment Cell Res. 1, 133-136.
91. Lindquist N. G., Larsson B. S., and, Lyden-Sokolowski A., (1988) Autoradiography of [14C]paraquat or [14C]diquat in frogs and mice: accumulation in neuromelanin. Neurosci. Lett. 93, 1-6.
92. Linert W., Herlinger E., Jameson R. F., Kienzl E., Jellinger K., and, Youdim M. B., (1996) Dopamine, 6-hydroxydopamine, iron, and dioxygen-their mutual interactions and possible implication in the development of Parkinson's disease. Biochim. Biophys. Acta 1316, 160-168.
93. Lozano J., Muñoz P., Nore B. F., Ledoux S., and, Segura-Aguilar J., (2010) Stable expression of short interfering RNA for DT-diaphorase induces neurotoxicity. Chem. Res. Toxicol. 23, 1492-1496.
94. Makin O. S., and, Serpell L. C., (2005) Structures for amyloid fibrils. FEBS J. 272, 5950-5961.
95. Marin C., and, Obeso J. A., (2010) Catechol-O-methyltransferase inhibitors in preclinical models as adjuncts of L-dopa treatment. Int. Rev. Neurobiol. 95, 191-205.
96. Marsden C. D., (1983) Neuromelanin and Parkinson's disease. J. Neural Transm. Suppl. 19, 121-141.
97. Martinez-Vicente M., and, Vila M., (2013) Alpha-synuclein and protein degradation pathways in Parkinson's disease: a pathological feed-back loop. Exp. Neurol. 247, 308-313.
98. Mattammal M. B., Strong R., Lakshmi V. M., Chung H. D., and, Stephenson A. H., (1995) Prostaglandin H synthetase-mediated metabolism of dopamine: implication for Parkinson's disease. J. Neurochem. 64, 1645-1654.
99. McGeer P. L., Itagaki S., Boyes B. E., and, McGeer E. G., (1988) Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 38, 1285-1291.
100. Merad-Boudia M., Nicole A., Santiard-Baron D., Saillé C., and, Ceballos-Picot I., (1998) Mitochondrial impairment as an early event in the process of apoptosis induced by glutathione depletion in neuronal cells: relevance to Parkinson's disease. Biochem. Pharmacol. 56, 645-655.
101. Miller G. W., Erickson J. D., Perez J. T., Penland S. N., Mash D. C., Rye D. B., and, Levey A. I., (1999) Immunochemical analysis of vesicular monoamine transporter (VMAT2) protein in Parkinson's disease. Exp. Neurol. 156, 138-148.
102. Mullin S., and, Schapira A., (2013) α-Synuclein and mitochondrial dysfunction in Parkinson's disease. Mol. Neurobiol. 47, 587-597.
103. Muñoz P., Paris I., Sanders L. H., Greenamyre J. T., and, Segura-Aguilar J., (2012) Overexpression of VMAT-2 and DT-diaphorase protects substantia nigra-derived cells against aminochrome neurotoxicity. Biochim. Biophys. Acta 1822, 1125-1136.
104. Myöhänen T. T., Schendzielorz N., and, Männistö P. T., (2010) Distribution of catechol-O-methyltransferase (COMT) proteins and enzymatic activities in wild-type and soluble COMT deficient mice. J. Neurochem. 113, 1632-1643.
105. Napolitano A., Manini P., and, d'Ischia M., (2011) Oxidation chemistry of catecholamines and neuronal degeneration: an update. Curr. Med. Chem. 18, 1832-1845.
106. Nicolis S., Zucchelli M., Monzani E., and, Casella L., (2008) Myoglobin modification by enzyme-generated dopamine reactive species. Chem. Eur. J. 14, 8661-8673.
107. Norris E. H., Giasson B. I., Hodara R., Xu S., Trojanowski J. Q., Ischiropoulos H., and, Lee V. M., (2005) Reversible inhibition of alpha-synuclein fibrillization by dopaminochrome-mediated conformational alterations. J. Biol. Chem. 280, 21212-21219.
108. Paris I., Dagnino-Subiabre A., Marcelain K., Bennett L. B., Caviedes P., Caviedes R., Olea-Azar C., and, Segura-Aguilar J., (2001) Copper neurotoxicity is dependent on dopamine-mediated copper uptake and one-electron reduction of aminochrome in a rat substantia nigra neuronal cell line. J. Neurochem. 77, 519-529.
109. Paris I., Martinez-Alvarado P., Perez-Pastene C., Vieira M. N., Olea-Azar C., Raisman-Vozari R., Cardenas S., Graumann R., Caviedes P., and, Segura-Aguilar J., (2005a) Monoamine transporter inhibitors and norepinephrine reduce dopamine-dependent iron dependent iron toxicity in cells derived from the substantia nigra. J. Neurochem. 92, 1021-1032.
110. Paris I., Martinez-Alvarado P., Cardenas S., Perez-Pastene C., Graumann R., Fuentes P., Olea-Azar C., Caviedes P., and, Segura-Aguilar J., (2005b) Dopamine-dependent iron toxicity in cells derived from rat hypothalamus. Chem. Res. Toxicol. 18, 415-419.
111. Paris I., Perez-Pastene C., Couve E., Caviedes P., Ledoux S., and, Segura-Aguilar J., (2009) Copper dopamine complex induces mitochondrial autophagy preceding caspase-independent apoptotic cell death. J. Biol. Chem. 284, 13306-13315.
112. Paris I., Perez-Pastene C., Cardenas S., Iturriaga-Vasquez P., Muñoz P., Couve E., Caviedes P., and, Segura-Aguilar J., (2010) Aminochrome induces disruption of actin, alpha-, and beta-tubulin cytoskeleton networks in substantia-nigra-derived cell line. Neurotox. Res. 18, 82-92.
113. Paris I., Muñoz P., Huenchuguala S., Couve E., Sanders L. H., Greenamyre J. T., Caviedes P., and, Segura-Aguilar J., (2011) Autophagy protects against aminochrome-induced cell death in substantia nigra-derived cell line. Toxicol. Sci. 121, 376-388.
114. Pezzella A., Crescenzi O., Natangelo A., Panzella L., Napolitano A., Navaratnam S., Edge R., Land E. J., Barone V., and, d'Ischia M., (2007) Chemical, pulse radiolysis and density functional studies of a new, labile 5,6-indolequinone and its semiquinone. J. Org. Chem. 72, 1595-1603.
115. Polymeropoulos M. H., Lavedan C., Leroy E., et al,. (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276, 2045-2047.
116. Ramirez A., Heimbach A., Gründemann J., et al,. (2006) Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat. Genet. 38, 1184-1191.
117. Rohn T. T., (2012) Targeting alpha-synuclein for the treatment of Parkinson's disease. CNS Neurol. Disord. Drug Targets. 11, 174-179.
118. Rosengren E., Linder-Eliasson E., and, Carlsson A., (1985) Detection of 5-S-cysteinyldopamine in human brain. J. Neural. Transm. 63, 247-253.
119. Salazar M., Sokoloski T. D., and, Patil P. N., (1978) Binding of dopaminergic drugs by the neuromelanin of the substantia nigra, synthetic melanins and melanin granules. Fed. Proc. 37, 2403-2407.
120. Saura J., Luque J. M., Cesura A. M., Da Prada M., Chan-Palay V., Huber G., Loffler J., and, Richards J. G., (1994) Increased monoamine oxidase B activity in plaque-Associated astrocytes of Alzheimer brains revealed by quantitative enzyme radioautography. Neuroscience 62, 15-30.
121. Schultzberg M., Segura-Aguilar J., and, Lind C., (1988) Distribution of DT diaphorase in the rat brain: biochemical and immunohistochemical studies. Neuroscience 27, 763-776.
122. Segura-Aguilar J., (1996) Peroxidase activity of liver microsomal vitamin D 25-hydroxylase and cytochrome P450 1A2 catalyzes 25-hydroxylation of vitamin D3 and oxidation of dopamine to aminochrome. Biochem. Mol. Med. 58, 122-129.
123. 3+ induced neurotoxicity of dopamine: prevention of quinone derived oxygen toxicity by DT-diaphorase and superoxide dismutase. Chem. Biol. Interact. 72, 309-324.
124. Segura-Aguilar J., Baez S., Widersten M., Welch C. J., and, Mannervik B., (1997) Human class Mu glutathione transferases, in particular isoenzyme M2-2, catalyze detoxication of the dopamine metabolite aminochrome. J. Biol. Chem. 272, 5727-5731.
125. Segura-Aguilar J., Metodiewa D., and, Welch C., (1998) Metabolic activation of dopamine o-quinones to o-semiquinones by NADPH cytochrome P450 reductase may play an important role in oxidative stress and apoptotic effects. Biochim. Biophys. Acta 1381, 1-6.
126. Segura-Aguilar J., Diaz-Veliz G., Mora S., and, Herrera-Marschitz M., (2002) Inhibition of DT-diaphorase is a requirement for Mn (III) to produce a 6-OH-dopamine like rotational behaviour. Neurotox. Res. 4, 127-131.
127. Shamoto-Nagai M., Maruyama W., Akao Y., Osawa T., Tribl F., Gerlach M., Zucca F. A., Zecca L., Riederer P., and, Naoi M., (2004) Neuromelanin inhibits enzymatic activity of 26S proteasome in human dopaminergic SH-SY5Y cells. J. Neural. Transm. 111, 1253-1265.
128. Shamoto-Nagai M., Maruyama W., Yi H., Akao Y., Tribl F., Gerlach M., Osawa T., Riederer P., and, Naoi M., (2006) Neuromelanin induces oxidative stress in mitochondria through release of iron: mechanism behind the inhibition of 26S proteasome. J. Neural. Transm. 113, 633-644.
129. Shen X. M., Xia B., Wrona M. Z., and, Dryhurst G., (1996) Synthesis, redox properties, in vivo formation, and neurobehavioral effects of N-Acetylcysteinyl conjugates of dopamine: possible metabolites of relevance to Parkinson's disease. Chem. Res. Toxicol. 9, 1117-1126.
130. Shih J. C., (1991) Molecular basis of human MAO A and B. Neuropsychopharmacology 4, 1-7.
131. Shih J. C., Grimsby J., and, Chen K., (1997) Molecular biology of monoamine oxidase A and B: their role in the degradation of serotonin, in Handbook of Experimental Pharmacology. Serotoninergic Neurons and 5-HT Receptors in the CNS (, Baumgarten H. G., and, Gothert M., eds), Vol. 129, pp. 655-670. Springer-Verlag, Berlin.
132. Shima T., Sarna T., Swartz H. M., Stroppolo A., Gerbasi R., and, Zecca L., (1997) Binding of iron to neuromelanin of human substantia nigra and synthetic melanin: an electron paramagnetic resonance spectroscopy study. Free Radic. Biol. Med. 23, 110-119.
133. Sofic E., Riederer P., Heinsen H., Beckmann H., Reynolds G. P., Hebenstreit G., and, Youdim M. B., (1988) Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain. J. Neural. Transm. 74, 199-205.
134. Stokes A. H., Hastings T. G., and, Vrana K. E., (1999) Cytotoxic and genotoxic potential of dopamine. J. Neurosci. Res. 55, 659-665.
135. Strolin-Benedetti M., Dostert P., and, Tipton K. F., (1992) Developmental aspects of the monoamine-degrading enzyme monoamine oxidase. Dev. Pharmacol. Ther. 18, 191-200.
136. Subramaniam S. R., and, Chesselet M. F., (2013) Mitochondrial dysfunction and oxidative stress in Parkinson's disease. Prog. Neurobiol. 107, 17-32.
137. Sulzer D., and, Zecca L., (2000) Intraneuronal dopamine-quinone synthesis: a review. Neurotox. Res. 1, 181-195.
138. Sulzer D., Bogulavsky J., Larsen K. E., et al,. (2000) Neuromelanin biosynthesis is driven by excess cytosolic catecholamines not accumulated by synaptic vesicles. Proc. Natl Acad. Sci. USA 97, 11869-11874.
139. Sulzer D., Mosharov E., Talloczy Z., Zucca F. A., Simon J. D., and, Zecca L., (2008) Neuronal pigmented autophagic vacuoles: lipofuscin, neuromelanin, and ceroid as macroautophagic responses during aging and disease. J. Neurochem. 106, 24-36.
140. Taylor J. M., Main B. S., and, Crack P. J., (2013) Neuroinflammation and oxidative stress: Co-conspirators in the pathology of Parkinson's disease. Neurochem. Int. 62, 803-819.
141. Thompson M., Capdevila J. H., and, Strobel H. W., (2000) Recombinant cytochrome P450 2D18 metabolism of dopamine and arachidonic acid. J. Pharmacol. Exp. Ther. 294, 1120-1130.
142. Trempe J. F., and, Fon E. A., (2013) Structure and function of parkin, PINK1, and DJ-1, the three musketeers of neuroprotection. Front Neurol. 4, 38.
143. Tribl F., Gerlach M., Marcus K., Asan E., Tatschner T., Arzberger T., Meyer H. E., Bringmann G., and, Riederer P., (2005) "Subcellular proteomics" of neuromelanin granules isolated from the human brain. Mol. Cell. Proteomics 4, 945-957.
144. Tribl F., Arzberger T., Riederer P., and, Gerlach M., (2007) Tyrosinase is not detected in human catecholaminergic neurons by immunohistochemistry and Western blot analysis. J. Neural Transm. Suppl. 72, 51-55.
145. Trinh J., and, Farrer M., (2013) Advances in the genetics of Parkinson disease. Nat Rev. Neurol. 9, 445-454.
146. Tse D. C., McCreery R. L., and, Adams R. N., (1976) Potential oxidative pathways of brain catecholamines. J. Med. Chem. 19, 37-40.
147. Valente E. M., Abou-Sleiman P. M., Caputo V., et al,. (2004) Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 304, 1158-1160.
148. Van Laar V. S., Dukes A. A., Cascio M., and, Hastings T. G., (2008) Proteomic analysis of rat brain mitochondria following exposure to dopamine quinone: implications for Parkinson disease. Neurobiol. Dis. 29, 477-489.
149. Van Laar V. S., Mishizen A. J., Cascio M., and, Hastings T. G., (2009) Proteomic identification of dopamine-conjugated proteins from isolated rat brain mitochondria and SH-SY5Y cells. Neurobiol. Dis. 34, 487-500.
150. Wakamatsu K., Fujikawa K., Zucca F. A., Zecca L., and, Ito S., (2003) The structure of neuromelanin as studied by chemical degradative methods. J. Neurochem. 86, 1015-1023.
151. Wakamatsu K., Murase T., Zucca F. A., Zecca L., and, Ito S., (2012) Biosynthetic pathway to neuromelanin and its aging process. Pigment Cell Melanoma Res. 25, 792-803.
152. Wang N., Wang Y., Yu G., Yuan C., and, Ma J., (2011) Quinoprotein adducts
153. Ward W. C., Guan Z., Zucca F. A., Fariello R. G., Kordestani R., Zecca L., Raetz C. R., and, Simon J. D., (2007) Identification and quantification of dolichol and dolichoic acid in neuromelanin from substantia nigra of the human brain. J. Lipid Res. 48, 1457-1462.
154. Weinreb O., Amit T., Riederer P., Youdim M. B., and, Mandel S. A., (2011) Neuroprotective profile of the multitarget drug rasagiline in Parkinson's disease. Int. Rev. Neurobiol. 100, 127-149.
155. Westlund K. N., Denney R. M., Rose R. M., and, Abell C. W., (1988) Localization of distinct monoamine oxidase A and monoamine oxidase B cell populations in human brainstem. Neuroscience 25, 439-456.
156. Weyler W., Hsu Y. P., and, Breakefield X. O., (1990) Biochemistry and genetics of monoamine oxidase. Pharmacol. Ther. 47, 391-417.
157. Whitehead R. E., Ferrer J. V., Javitch J. A., and, Justice J. B., (2001) Reaction of oxidized dopamine with endogenous cysteine residues in the human dopamine transporter. J. Neurochem. 76, 1242-1251.
158. Wilms H., Rosenstiel P., Sievers J., Deuschl G., Zecca L., and, Lucius R., (2003) Activation of microglia by human neuromelanin is NF-kappaB dependent and involves p38 mitogen-Activated protein kinase: implications for Parkinson's disease. Faseb J. 17, 500-502.
159. Wolters E. Ch., and, Braak H., (2006) Parkinson's disease: premotor clinico-pathological correlations. J. Neural Transm. Suppl. 70, 309-319.
160. Xu Y., Stokes A. H., Freeman W. M., Kumer S. C., Vogt B. A., and, Vrana K. E., (1997) Tyrosinase mRNA is expressed in human substantia nigra. Brain Res. Mol. Brain Res. 45, 159-162.
161. Xu Y., Stokes A. H., Roskoski R., Jr, and, Vrana K. E., (1998) Dopamine, in the presence of tyrosinase, covalently modifies and inactivates tyrosine hydroxylase. J. Neurosci. Res. 54, 691-697.
162. Zafar K. S., Siegel D., and, Ross D., (2006) A potential role for cyclized quinones derived from dopamine, DOPA, and 3,4-dihydroxyphenylacetic acid in proteasomal inhibition. Mol. Pharmacol. 70, 1079-1086.
163. Zareba M., Bober A., Korytowski W., Zecca L., and, Sarna T., (1995) The effect of a synthetic neuromelanin on yield of free hydroxyl radicals generated in model systems. Biochim. Biophys. Acta 1271, 343-348.
164. Zecca L., Pietra R., Goj C., Mecacci C., Radice D., and, Sabbioni E., (1994) Iron and other metals in neuromelanin, substantia nigra, and putamen of human brain. J. Neurochem. 62, 1097-1101.
165. Zecca L., Costi P., Mecacci C., Ito S., Terreni M., and, Sonnino S., (2000) Interaction of human substantia nigra neuromelanin with lipids and peptides. J. Neurochem. 74, 1758-1765.
166. Zecca L., Tampellini D., Costi P., Rizzio E., Giaveri G., and, Gallorini M., (2001a) Combined biochemical separation and INAA for the determination of iron and other metals in Neuromelanin of human brain Substantia Nigra. J. Radioanal. Nucl. Chem. 249, 449-454.
167. Zecca L., Gallorini M., Schünemann V., Trautwein A. X., Gerlach M., Riederer P., Vezzoni P., and, Tampellini D., (2001b) Iron, neuromelanin and ferritin content in the substantia nigra of normal subjects at different ages: consequences for iron storage and neurodegenerative processes. J. Neurochem. 76, 1766-1773.
168. Zecca L., Fariello R., Riederer P., Sulzer D., Gatti A., and, Tampellini D., (2002) The absolute concentration of nigral neuromelanin, assayed by a new sensitive method, increases throughout the life and is dramatically decreased in Parkinson's disease. FEBS Lett. 510, 216-220.
169. Zecca L., Youdim M. B., Riederer P., Connor J. R., and, Crichton R. R., (2004) Iron, brain ageing and neurodegenerative disorders. Nat. Rev. Neurosci. 5, 863-873.
170. Zecca L., Bellei C., Costi P., et al,. (2008a) New melanic pigments in the human brain that accumulate in aging and block environmental toxic metals. Proc. Natl Acad. Sci. USA 105, 17567-17572.
171. Zecca L., Casella L., Albertini A., Bellei C., Zucca F. A., Engelen M., Zadlo A., Szewczyk G., Zareba M., and, Sarna T., (2008b) Neuromelanin can protect against iron-mediated oxidative damage in system modeling iron overload of brain aging and Parkinson's disease. J. Neurochem. 106, 1866-1875.
172. Zecca L., Wilms H., Geick S., et al,. (2008c) Human neuromelanin induces neuroinflammation and neurodegeneration in the rat substantia nigra: implications for Parkinson's disease. Acta Neuropathol. 116, 47-55.
173. Zhang W., Phillips K., Wielgus A. R., et al,. (2011) Neuromelanin activates microglia and induces degeneration of dopaminergic neurons: implications for progression of Parkinson's disease. Neurotox. Res. 19, 63-72.
174. Zhang W., Zecca L., Wilson B., Ren H. W., Wang Y. J., Wang X. M., and, Hong J. S., (2013) Human neuromelanin: an endogenous microglial activator for dopaminergic neuron death. Front. Biosci. (Elite Ed) 1, 1-11.
175. Zhou Z. D., and, Lim T. M., (2009) Dopamine (DA) induced irreversible proteasome inhibition via DA derived quinones. Free Radic. Res. 43, 417-430.
176. Zucca F. A., Basso E., Cupaioli F. A., Ferrari E., Sulzer D., Casella L., and, Zecca L., (2014) Neuromelanin of the human substantia nigra: an update. Neurotox. Res. 25, 13-23. Tecnológico Tecnológico